Evidence map›Paper›PMID 40847231›Full record

ReviewCancer treatment and research2025

Immunotherapy in Glioblastoma.

Andrew Williams, Rimas V Lukas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andrew WilliamsDepartment of Neurology, Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Evanston, IL, USA.
Rimas V LukasDepartment of Neurology, Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Evanston, IL, USA. rimas.lukas@nm.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapies continue to hold promise for the treatment of glioblastoma, a malignant central nervous system tumor. Thus far, success utilizing this approach has been limited. Negative trials with vaccines and immune checkpoint inhibitors have been unable to demonstrate improvement in survival, however, they have provided insights into hurdles which need to be overcome. Ongoing investigations into modulation of the highly suppressed tumor immune microenvironment, direct simulation of the immune system for proinflammatory effect, and the use of cellular therapies will help inform future therapeutic directions.

Indexed as

Brain NeoplasmsGlioblastomaImmunotherapyCancer VaccinesHumansImmune Checkpoint InhibitorsTumor MicroenvironmentCancer VaccinesImmune Checkpoint InhibitorsCellular therapyCheckpoint inhibitorGlioblastomaImmunotherapyTumor microenvironmentVaccine

Identifiers

PMID40847231

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.